At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients >/= 60 Years Old With Acute Myeloid Leukemia (AML)
In Brief
A Phase 2 clinical trial evaluating Bortezomib, Decitabine, and 4 other interventions for Acute Myeloid Leukemia and 2 related conditions. Completed, enrolled 165 participants across 53 sites.
Detailed Summary
This randomized phase II trial studies how well giving decitabine with or without bortezomib works in treating older patients with acute myeloid leukemia. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells,by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether decitabine works better when given with or without bortezomib in treating acute myeloid leukemia.
Study Details
Timeline
Interventions
Given SC
Given IV
Correlative studies
Correlative studies
Ancillary studies
Ancillary studies